Cargando…

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis

Detalles Bibliográficos
Autores principales:	Ahidjo, Bintou Ahmadou, Bishai, William R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776226/ https://www.ncbi.nlm.nih.gov/pubmed/26981560 http://dx.doi.org/10.1016/j.ebiom.2016.02.016

Ejemplares similares

Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis
por: Maiga, Mamoudou, et al.
Publicado: (2015)

Erratum to “Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis” [EBioMedicine 2 (8), August 2015, 868–873]
por: Maiga, Mamoudou, et al.
Publicado: (2015)

Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis
por: Dorhoi, Anca
Publicado: (2015)

Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model
por: Subbian, Selvakumar, et al.
Publicado: (2016)

Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model
por: Maiga, Mamoudou, et al.
Publicado: (2012)

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial
por: Wallis, Robert S, et al.
Publicado: (2021)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
por: Simkova, Vladislava, et al.
Publicado: (2007)

VapC Toxins from Mycobacterium tuberculosis Are Ribonucleases that Differentially Inhibit Growth and Are Neutralized by Cognate VapB Antitoxins
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2011)

Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
por: Dalamaga, Maria, et al.
Publicado: (2020)

Cyclic nucleotide phosphodiesterase 1 and vascular aging
por: Yan, Chen
Publicado: (2015)

Adjunctive Integrated Stress Response Inhibition Accelerates Tuberculosis Clearance in Mice
por: Krug, Stefanie, et al.
Publicado: (2023)

Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
por: Solaimanzadeh, Isaac
Publicado: (2020)

Arginine Adjunctive Therapy in Active Tuberculosis
por: Farazi, Aliasghar, et al.
Publicado: (2015)

Cognitive Stimulation Therapy as an Adjunctive Treatment for Mild to Moderate Dementia
por: Kumar, S. Sandeep, et al.
Publicado: (2023)

Adjunctive corticosteroid therapy in patients with pulmonary tuberculosis
por: Lemos, Carolina Xavier, et al.
Publicado: (2022)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis
por: Krug, Stefanie, et al.
Publicado: (2021)

Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder
por: Abdallah, Mahmoud S., et al.
Publicado: (2021)

Commentary: Platelet-rich plasma is a useful adjunct but with caveats
por: Shanmugam, P Mahesh
Publicado: (2020)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021)

Commentary: Can cryotherapy be used as an adjunct in select cases of recalcitrant endophthalmitis?
por: Das, Tarprasad
Publicado: (2019)

Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
por: Torphy, T J, et al.
Publicado: (1994)

Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis
por: Leukes, Vinzeigh, et al.
Publicado: (2020)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

Commentary: Adjunctive agents in peribulbar anesthesia: Role of dexmedetomidine in vitreo-retinal surgeries
por: Bhandari, Sahil
Publicado: (2019)

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial
por: Wallis, Robert S., et al.
Publicado: (2022)

Two commentaries on ‘Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children’
por: Coovadia, Hoosen, et al.
Publicado: (2009)

Mycobacterium tuberculosis-Associated Necrotizing Pneumonia With Adjunctive Corticosteroid Therapy
por: Nguyen, Ho Lam, et al.
Publicado: (2019)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy
por: Wen, Jian-jun, et al.
Publicado: (2016)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_ug8tt5vatjqa5mnlctdfcmp6co